<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04991948</url>
  </required_header>
  <id_info>
    <org_study_id>CYAD-101-002</org_study_id>
    <secondary_id>KEYNOTE-B79</secondary_id>
    <nct_id>NCT04991948</nct_id>
  </id_info>
  <brief_title>Phase 1b Study to Evaluate the Addition of a Pembrolizumab Treatment After Treatment With CYAD-101 With a FOLFOX Preconditioning in Metastatic Colorectal Cancer Patients</brief_title>
  <official_title>An Open-label, Phase Ib Study to Assess the Safety and Clinical Activity of CYAD-101 Administered Concurrently With FOLFOX Chemotherapy, Followed by Pembrolizumab Treatment, in Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celyad Oncology SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Celyad Oncology SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the CYAD-101-002 study is to assess the safety and clinical activity of&#xD;
      CYAD-101 in patients with unresectable metastatic colorectal cancer administered concurrently&#xD;
      with FOLFOX chemotherapy, followed by pembrolizumab treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Study aims to provide insight into whether CYAD-101 administration concurrently with&#xD;
      FOLFOX chemotherapy, followed by pembrolizumab treatment might be a treatment option for&#xD;
      patients with unresectable metastatic colorectal cancer&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">May 25, 2038</completion_date>
  <primary_completion_date type="Anticipated">August 21, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Occurrence of Dose Limiting Toxicities (DLT) during the 'DLT reporting period'</measure>
    <time_frame>Up to 73 days post first study treatment administration</time_frame>
    <description>The occurrence of DLT during the 'DLT reporting period' is defined as the period from study enrollment on D1 (Visit 1) up to 3 weeks after first pembrolizumab treatment on D73 (Visit 14).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The objective response rate (ORR) at the tumor assessment on Day 94 [Visit 15])</measure>
    <time_frame>Up to 94 days post first study treatment administration</time_frame>
    <description>The objective response rate (ORR) at the tumor assessment on Day 94 [Visit 15]), 6 weeks after the first pembrolizumab treatment administration.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Unresectable Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>CYAD-101 with FOLFOX Infusion administered concurrently followed by pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYAD-101</intervention_name>
    <description>Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells</description>
    <arm_group_label>CYAD-101 with FOLFOX Infusion administered concurrently followed by pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX</intervention_name>
    <description>5-FU, leucovorin and oxaliplatin</description>
    <arm_group_label>CYAD-101 with FOLFOX Infusion administered concurrently followed by pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb)</description>
    <arm_group_label>CYAD-101 with FOLFOX Infusion administered concurrently followed by pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Histologically proven metastatic adenocarcinoma of the colon or rectum.&#xD;
&#xD;
               1. Confirmed metastatic unresectable adenocarcinoma of the colon or the rectum.&#xD;
&#xD;
               2. Confirmed non-microsatellite instability high (non-MSI-H)/mismatch-repair&#xD;
                  proficient (pMMR) tumor status&#xD;
&#xD;
               3. Unequivocal and measurable disease by Response Evaluation Criteria in Solid&#xD;
                  Tumors (RECIST version 1.1).&#xD;
&#xD;
               4. Recurrent/progressing disease after at least one line of systemic therapy for&#xD;
                  metastatic disease which must include FOLFOX chemotherapy&#xD;
&#xD;
               5. The patient is due to receive FOLFOX chemotherapy&#xD;
&#xD;
               6. Neurotoxicity less than or equal to Common Terminology Criteria for Adverse&#xD;
                  Events (CTCAE) Grade 1 from previous chemotherapy.&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.&#xD;
&#xD;
          3. Adequate organ, hepatic, renal, pulmonary and cardiac functions&#xD;
&#xD;
          4. Tumor biopsy at screening&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Any other investigational agent or device within 4 weeks of the first study treatment&#xD;
             administration.&#xD;
&#xD;
          2. Any anticancer agent within 4 weeks of the first study treatment administration&#xD;
&#xD;
          3. Filgrastim (Granulocyte-Colony-Stimulating Factor [G-CSF]) or similar growth factors&#xD;
             within 7 days of the first study treatment administration&#xD;
&#xD;
          4. Prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent&#xD;
             directed to another stimulatory or co-inhibitory T-cell receptor&#xD;
&#xD;
          5. Prior radiotherapy within 2 weeks prior to the planned day for the first study&#xD;
             treatment administration&#xD;
&#xD;
          6. Major surgery within 4 weeks before the planned day for the first study treatment&#xD;
             administration&#xD;
&#xD;
          7. A live vaccine within 30 days prior to the planned day for the first study treatment&#xD;
             administration&#xD;
&#xD;
          8. Uncontrolled intercurrent illness or serious uncontrolled medical disorder&#xD;
&#xD;
          9. Patients with history of (non-infectious) pneumonitis that require steroids or has&#xD;
             current pneumonitis as assessed by chest imaging within 48 hours prior to first study&#xD;
             treatment administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Celyad Oncology Medical Monitor, MD, PhD</last_name>
    <phone>+3210394100</phone>
    <email>clinicaltrials@celyad.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Moffit Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kim Dae Won, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kim Dae Won</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>EMORY University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria Diab, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria Diab, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Hans Prenen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hans Prenen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Hilde Marse</last_name>
    </contact>
    <investigator>
      <last_name>Eric Van Cutsem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

